Journey Medical (NASDAQ:DERM) Issues Quarterly Earnings Results

Journey Medical (NASDAQ:DERM) announced its quarterly earnings data on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03), Yahoo Finance reports. Journey Medical had a negative return on equity of 32.83% and a negative net margin of 5.20%. The firm had revenue of $14.86 million during the quarter, compared to analysts’ expectations of $13.81 million. During the same period last year, the company earned ($0.46) earnings per share.

Journey Medical Trading Down 9.3 %

DERM traded down $0.45 during trading on Wednesday, hitting $4.37. 25,626 shares of the company traded hands, compared to its average volume of 134,955. The company has a market cap of $87.46 million, a P/E ratio of -15.55 and a beta of 0.93. Journey Medical has a 1 year low of $1.78 and a 1 year high of $8.11. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.94 and a current ratio of 1.21. The stock has a 50-day moving average price of $5.31.

Insiders Place Their Bets

In other news, CFO Joseph Benesch sold 9,324 shares of Journey Medical stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $5.47, for a total value of $51,002.28. Following the sale, the chief financial officer now directly owns 47,331 shares of the company’s stock, valued at $258,900.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 19.42% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on DERM. Roth Mkm initiated coverage on shares of Journey Medical in a report on Friday, June 28th. They issued a “buy” rating and a $11.00 target price for the company. Roth Capital raised Journey Medical to a “strong-buy” rating in a research note on Friday, June 28th.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.